Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide maintenance therapy in primary multiple myeloma
ChiCTR2200057019Phase 4Not yet recruiting
- Sponsor
- The First Hospital of Lanzhou University
- Start
- Feb 2022
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pomalidomide in multiple myeloma (MM), sponsored by The First Hospital of Lanzhou University. Primary endpoint: Complete remission and very good partial remission. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2200057019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057019.